US Health Moves And Quality of Care

21 August 1994

Quality of care should be dealt with in the same way as issues of cost and access, says a white paper from the US Council of the Institute of Medicine, entitled America's Health in Transition: Protecting and Improving the Quality of Health and Health Care.

The fundamental quality issues which it identifies are: - unnecessary or inappropriate care such as overprescribing antibiotics and excessive use of surgery, which could have harmful side effects and waste money and resources; - underuse of preventative and clinical care due to no insurance cover, managed care arrangements or geographical, cultural or other barriers; and - shortcomings in technical and interpersonal aspects of care. IoM president and council chairman Kenneth Shine said these issues are not considered adequately in several reform plans before Congress, and that new and enhanced measurement tools to assess the quality of care will be needed as the nation's concerns about quality change and its ability to gather and use data evolves.

The Council urges health plans and provider groups to act on their own to measure and improve their performance and patient outcomes so that intrusive programs to micromanage care from the outside can be avoided. But external monitoring will be needed to ensure the integrity of quality management procedures and information, and to assess the population's health. More must be learned about the appropriate contents of "report cards" and how consumers would use this information to make safe choices, it adds.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight